Trial Profile
Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Without Intracranial Hypertension Brain Metastases: A Prospective Multicenter Trial(TRACTS).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TRACTS
- 24 Jan 2013 New trial record